Summit plays defense for the first time as questions loom over Phase 3 datanews2025-09-08T19:01:44+00:00September 8th, 2025|Endpoints News|
Pfizer reports new Covid-19 vaccine data from open-label studynews2025-09-08T18:13:38+00:00September 8th, 2025|Endpoints News|
Eli Lilly’s Jaypirca shows ‘striking’ results in first-line lymphoma patients news2025-09-08T17:22:51+00:00September 8th, 2025|Endpoints News|
Dianthus’ selective complement inhibitor yields Phase 2 success in myasthenia gravisnews2025-09-08T15:29:39+00:00September 8th, 2025|Endpoints News|
#WCLC25: BioNTech, Bristol Myers tout PD-L1xVEGF results in small cell lung cancernews2025-09-08T15:00:45+00:00September 8th, 2025|Endpoints News|
Rapport reveals promising open-label study data for epilepsy pill, heads to Phase 3news2025-09-08T10:00:35+00:00September 8th, 2025|Endpoints News|
#WCLC25: AstraZeneca’s Tagrisso combo extends survival by 10 months in EGFR-mutant lung cancernews2025-09-08T08:22:44+00:00September 8th, 2025|Endpoints News|
#WorldSleep2025: Alkermes’ success in Phase 2 narcolepsy trial is clouded by side effectsnews2025-09-08T07:15:52+00:00September 8th, 2025|Endpoints News|
#WorldSleep2025: Takeda’s Phase 3 narcolepsy results could make it first mover in multibillion-dollar marketnews2025-09-08T07:15:19+00:00September 8th, 2025|Endpoints News|
Mitochondrial startup gets £50M to test lead drug in ALS, Parkinson’snews2025-09-08T07:00:40+00:00September 8th, 2025|Endpoints News|
